Interleukin-15 receptor-directed immunotoxins atteunuate disease severity in rat adjuvant arthritis

Molecular Immunology

Volumn 47, Issue 7-8, 2010, Pages 1535-1543

  Wang, Deling ^a   Deng, Xianglei ^a   Leng, Xiaoyan ^a   Mao, Xiaohua ^a  

^a SOUTHEAST UNIVERSITY   (China)

Author keywords

Animal model; Cytokines; IL 15; Immunotoxin; Pseudomonas exotoxin; Rheumatoid arthritis; Therapy

Indexed keywords

INTERLEUKIN 15 PSEUDOMONAS EXOTOXIN DELTA 293; INTERLEUKIN 15 RECEPTOR; INTERLEUKIN 15M DELTA 293; MESSENGER RNA; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ADJUVANT ARTHRITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY TEST; DISEASE SEVERITY; DRUG EFFICACY; LEUKOCYTE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; PROTEIN TARGETING; RAT; SIGNAL TRANSDUCTION; TREATMENT DURATION; TREATMENT RESPONSE;

ANIMALS; ARTHRITIS, EXPERIMENTAL; CELL LINE, TUMOR; GENE EXPRESSION REGULATION; HUMANS; IMMUNOTOXINS; MALE; PHOSPHORYLATION; PSEUDOMONAS; RATS; RATS, WISTAR; RECEPTORS, INTERLEUKIN-15; STAT3 TRANSCRIPTION FACTOR;

ANIMALIA; PSEUDOMONAS EXOTOXIN; RATTUS;

EID: 77950626672     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2010.01.023     Document Type: Article

References (41)

1. Alleva D.G., Kaser S.B., Monroy M.A., Fenton M.J., Beller D.I. IL-15 functions as a potent autocrine regulator of macrophage proinflammatory cytokine production. J. Immunol. 1997, 159:2941-2951.
2. Asquith D.L., McInnes I.B. Emerging cytokine targets in rheumatoid arthritis. Curr. Opin. Rheumatol. 2007, 19:246-251.
3. Baslund B., Tvede N., Danneskiold-Samsoe B., Larsson P., Panayi G., Petersen J., Petersen L.J., Beurskens F.J., Schuurman J., van de Winkel J.G., Parren P.W., Gracie J.A., Jongbloed S., Liew F.Y., McInnes I.B. Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study. Arthritis Rheum. 2005, 52:2686-2692.
4. Bradfield P.F., Amft N., Vernon-Wilson E., Exley A.E., Parsonage G., Rainger G.E., Nash G.B., Thomas A.M., Simmons D.L., Salmon M., Buckley C.D. Rheumatoid fibroblast-like synoviocytes overexpress the chemokine stromal cell-derived factor 1 (CXCL12), which supports distinct patterns and rates of CD4+ and CD8+ T cell migration within synovial tissue. Arthritis Rheum. 2003, 48:2472-2482.
5. Case J.P., Lorberboum-Galski H., Lafyatis R., FitzGerald D., Wilder R.L., Pastan I. Chimeric cytotoxin IL2-PE40 delays and mitigates adjuvant-induced arthritis in ratss. Proc. Natl. Acad. Sci. U.S.A. 1989, 86:287-291.
6. Chan A., Filer A., Parsonage G., Kollnberger S., Gundle R., Buckley C.D., Bowness P. Mediation of the proinflammatory cytokine response in rheumatoid arthritis and spondylarthritis by interactions between fibroblast-like synoviocytes and natural killer cells. Arthritis Rheum. 2008, 58:707-717.
7. Ernestam S., af Klint E., Catrina A.I., Sundberq E., Enqstrom M., Klareskoq L., Ulfgren A.K. Synovial expression of IL-15 in rheumatoid arthritis is not influenced by blockade of tumour necrosis factor. Arthritis Res. Ther. 2006, 8:R18.
8. Fehniger T.A., Caligiuri M.A. Interleukin 15: biology and relevance to human disease. Blood 2001, 97:14-32.
9. Feldmann M., Maini S.R. Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunol. Rev. 2008, 223:7-19.
10. Ferrari-Lacraz S., Zanelli E., Neuberg M., Donskoy E., Kim Y.S., Zheng X.X., Hancock W.W., Maslinski W., Li X.C., Strom T.B., Moll T. Targeting IL-15 receptor-bearing cells with an antagonist mutant IL-15/Fc protein prevents disease development and progression in murine collagen-induced arthritis. J. Immunol. 2004, 173:5818-5826.
11. Fossiez F., Djossou O., Chomarat P., Flores-Romo L., Ait-Yahia S., Maat C., Pin J.J., Garrone P., Garcia E., Saeland S., Blanchard D., Gaillard C., Das Mahapatra B., Rouvier E., Golstein P., Banchereau J., Lebecque S. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J. Exp. Med. 1996, 183:2593-2603.
12. Houchins J.P. Immunotoxin-induced apoptosis. Stem Cells 2000, 18:384-385.
13. Ivashkiv L.B., Hu X. The JAK/STAT pathway in rheumatoid arthritis: pathogenic or protective?. Arthritis Rheum. 2003, 48:2092-2096.
14. Jiang Y., Genant H.K., Watt I., Cobby M., Bresnihan B., Aitchison R., McCabe D. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum. 2000, 43:1001-1009.
15. Jovanovic D.V., Di Battista J.A., Martel-Pelletier J., Jolicoeur F.C., He Y., Zhang M., Mineau F., Pelletier J.P. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. J. Immunol. 1998, 160:3513-3521.
16. Kawakami A., Eguchi K. Involvement of apoptotic cell death in autoimmune diseases. Med. Electron Microsc. 2002, 35:1-8.
17. Kurowska M., Rudnicka W., Kontny E., Janicka I., Chorazy M., Kowalczewski J., Ziółkowska M., Ferrari-Lacraz S., Strom T.B., Maśliński W. Fibroblast-like synoviocytes from rheumatoid arthritis patients express functional IL-15 receptor complex: endogenous IL-15 in autocrine fashion enhances cell proliferation and expression of Bcl-xL and Bcl-2. J. Immunol. 2002, 169:1760-1767.
18. McInnes I.B., al-Mughales J., Field M., Leung B.P., Huang F.P., Dixon R., Sturrock R.D., Wilkinson P.C., Liew F.Y. The role of interleukin-15 in T-cell migration and activation in rheumatoid arthritis. Nat. Med. 1996, 2:175-182.
19. McInnes I.B., Leung B.P., Sturrock R.D., Field M., Liew F.Y. Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-alpha production in rheumatoid arthritis. Nat. Med. 1997, 3:189-195.
20. Miranda-Carús M.E., Balsa A., Benito-Miguel M., Pérez de Ayala C., Martín-Mola E. IL-15 and the initiation of cell contact-dependent synovial fibroblast-T lymphocyte cross-talk in rheumatoid arthritis: effect of methotrexate. J. Immunol. 2004, 173:1463-1476.
21. Moreland L.W., Baumgartner S.W., Schiff M.H., Tindall E.A., Fleischmann R.M., Weaver A.L., Ettlinger R.E., Cohen S., Koopman W.J., Mohler K., Widmer M.B., Blosch C.M. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N. Engl. J. Med. 1997, 337:141-147.
22. Nishimoto N., Yoshizaki K., Miyasaka N., Yamamoto K., Kawai S., Takeuchi T., Hashimoto J., Azuma J., Kishimoto T. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 2004, 50:1761-1769.
23. Niu Y.F., Mao X.H. Construction and in vitro cytotoxic assay of a novel fusion toxin IL15-PEΔ293. Chin. J. Microbiol. Immunol. 2004, 24:991-995.
24. Niu Y.F., Zheng Y., Mao X.H. Development of a fusion toxin IL15M-PEdelta293 based on a receptor-specific IL-15 antagonist. Sheng Wu Gong Cheng Xue Bao 2005, 21:42-46.
25. Oppenheimer-Marks N., Brezinschek R.I., Mohamadzadeh M., Vita R., Lipsky P.E. Interleukin-15 is produced by endothelial cells and increases the transendothelial migration of T-cells in vitro and in the SCID mouse-human rheumatoid arthritis model in vivo. J. Clin. Invest. 1998, 101:1261-1272.
26. Pastan I., Hassan R., FitzGerald D.J., Kreitman R.J. Immunotoxin therapy of cancer. Nat. Rev. Cancer 2006, 6:559-565.
27. Pettit D.K., Bonnert T.P., Eisenman J., Srinivasan S., Paxton R., Beers C., Lynch D., Miller B., Yost J., Grabstein K.H., Gombotz W.R. Structure-function studies of interleukin 15 using site-specific mutagenesis, polyethylene glycol conjugation, and homology modeling. J. Biol. Chem. 1997, 272:2312-2318.
28. Pierer M., Rethage J., Seibl R., Lauener R., Brentano F., Wagner U., Hantzschel H., Michel B.A., Gay R.E., Gay S., Kyburz D. Chemokine secretion of rheumatoid arthritis synovial fibroblasts stimulated by Toll-like receptor 2 ligands. J. Immunol. 2004, 172:1256-1265.
29. Pollard L., Choy E. Rheumatoid arthritis: non-tumor necrosis factor targets. Curr. Opin. Rheumatol. 2005, 17:242-246.
30. Pope R.M. Apoptosis as a therapeutic tool in rheumatoid arthritis. Nat. Rev. Immunol. 2002, 2:527-535.
31. Ruchatz H., Leung B.P., Wei X.Q., McInnes I.B., Liew F.Y. Soluble IL-15 receptor alpha-chain administration prevents murine collagen-induced arthritis: a role for IL-15 in development of antigen-induced immunopathology. J. Immunol. 1998, 160:5654-5660.
32. Ruckert R., Brandt K., Ernst M., Marienfeld K., Csernok E., Metzler C., Budagian V., Bulanova E., Paus R., Bulfone-Paus S. Interleukin-15 stimulates macrophages to activate CD4+ T cells: a role in the pathogenesis of rheumatoid arthritis?. Immunology 2009, 126:63-73.
33. Shahrara S., Pickens S.R., Dorfleutner A., Pope R.M. IL-17 induces monocyte migration in rheumatoid arthritis. J. Immunol. 2009, 182:3884-3891.
34. Shouda T., Yoshida T., Hanada T., Wakioka T., Oishi M., Miyoshi K., Komiya S., Kosai K., Hanakawa Y., Hashimoto K., Nagata K., Yoshimura A. Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis. J. Clin. Invest. 2001, 108:1781-1788.
35. Studier F.W., Rosenberg A.H., Dunn J.J., Dubendorff J.W. Use of T7 RNA polymerase to direct expression of cloned genes. Methods Enzymol. 1990, 185:60-89.
36. Taupiac M.-P., Bébien M., Alami M., Beaumelle B. A deletion within the translocation domain of Pseudomonas exotoxin A enhances translocation efficiency and cytotoxicity concomitantly. Mol. Microbiol. 1999, 31:1385-1393.
37. van Vuuren A.J., van Roon J.A., Walraven V., Stuij I., Harmsen M.C., McLaughlin P.M., van de Winkel J.G., Thepen T. CD64-directed immunotoxin inhibits arthritis in a novel CD64 transgenic rat model. J. Immunol. 2006, 176:5833-5838.
38. Voll R.E., Kalden J.R. Do we need new treatment that goes beyond tumor necrosis factor blockers for rheumatoid arthritis?. Ann. NY Acad. Sci. 2005, 1051:799-810.
39. Waldmann T.A., Tagaya Y. The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Annu. Rev. Immunol. 1999, 17:19-49.
40. Ziolkowska M., Koc A., Luszczykiewicz G., Ksiezopolska-Pietrzak K., Klimczak E., Chwalinska-Sadowska H., Maslinski W. High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporine A sensitive mechanism. J. Immunol. 2000, 164:2832-2838.
41. Zwerina J., Redlich K., Schett G., Smolen J.S. Pathogenesis of rheumatoid arthritis: targeting cytokines. Ann. NY Acad. Sci. 2005, 1051:716-729.